Pablo Corral Highlights CRIC Study: Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in CKD
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on Linkedin:
“Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease
New data from the CRIC study
In CKD patients without clinical CVD, aspirin use was associated with 38% lower MI risk and 28% lower ESRD risk — but only when Lp(a) ≥50 mg/dL.
No significant benefit was seen when Lp(a) <50 mg/dL, and bleeding risk did not increase.”
Title: Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort
Authors: Alexander C. Razavi, Jing Chen, Wei Yang, Daohang Sha, Omar Dzaye, Harpreet S. Bhatia, Sotirios Tsimikas, James P. Lash, Mayank Kansal, Hernan Rincon-Choles, Viola Vaccarino, Terry A. Jacobson, Matthew J. Budoff, Roger S. Blumenthal, Seamus P. Whelton, Laurence S. Sperling, Michael J. Blaha, Jiang H
Read the full article here.
Read more on Hemostasis Today.
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage
-
Oct 10, 2026, 02:17Dino Mehic: Managing Heavy Menstrual Bleeding in Patients with BDUC
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia